RxDoctor Payments Data

Shannon Harvey, OD

Optometrist · Florence, SCNPI 1689166019

Payments from drug & device makers

$2,274in general payments, 2019–2025

Across 50 payments — averaging $45.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • LKC Technologies, Inc.$249
  • Sun Pharmaceutical Industries Inc.$211
  • Mallinckrodt Hospital Products Inc.$173
  • Johnson & Johnson Vision Care, Inc.$163
  • Sight Sciences, Inc.$132
  • Rxsight Inc$128
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,274100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,274 in reported general payments places this provider in the 70th percentile of 653 optometrist providers in South Carolina.

See all optometrist providers in South Carolina

Medicare billing

Part B allowed, 2024
$120,004
Medicare patients
689
Services billed
1,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine56$61,555
XiidraLifitegrast41$34,083
Cyclosporine19$10,966
LumiganBimatoprost18$6,658
SimbrinzaBrinzolamide/Brimonidine Tart26$5,744
Prednisolone Acetate111$4,207
Brimonidine Tartrate166$3,210
Latanoprost275$3,031
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha179$2,209
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat110$1,793
Dorzolamide Hcl48$1,000
Timolol Maleate52$464
ErythromycinErythromycin Base36$369
Ofloxacin27$265
Azithromycin14$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$104$68,21474 claims
Bausch & Lomb Americas Inc.Xiidra$64$34,08341 claims
AlconSimbrinza$125$5,74426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 653 optometrist providers in South Carolina.

Other optometrist in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →